--- title: "Retatrutide | PepTracker Pro" description: "An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Retatrutide", "description": "An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.", "url": "https://peptrackerpro.com/peptides/retatrutide", "lastReviewed": "2026-06-13", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Retatrutide", "item": "https://peptrackerpro.com/peptides/retatrutide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following emerging obesity treatment research?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is a research peptide studied in preclinical models. An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." } }, { "@type": "Question", "name": "Those interested in triple agonist pharmacology?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is a research peptide studied in preclinical models. An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." } }, { "@type": "Question", "name": "Individuals comparing next-generation metabolic peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is a research peptide studied in preclinical models. An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Retatrutide **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. Aliases LY3437943 +1 more Evidence High Evidence Last Updated 2026-06-13 Reading Time 4 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Evidence Snapshot](#evidence-snapshot) 4. [Commonly Discussed Benefits](#benefits) 5. [Safety & Cautions](#safety) 6. [Comparisons](#comparisons) 7. [Calculator Tools](#calculator) 8. [Citations](#citations) ## What It Is Retatrutide (LY3437943) is an investigational triple incretin agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, developed by Eli Lilly. It is the first triple agonist to reach Phase 3 development and has produced the highest weight loss of any GLP-1-class therapy tested to date. In the Phase 3 TRIUMPH-4 trial (December 2025), retatrutide achieved 28.7% mean body weight loss at 68 weeks on the 12 mg dose — participants lost an average of 71.2 lbs (32.3 kg) from a baseline of 248.5 lbs, with 58.6% achieving ≥25% total body weight loss. Beyond weight, retatrutide reduced WOMAC knee pain scores by 75.8%, with more than 1 in 8 patients becoming completely pain-free — the first successful Phase 3 demonstrating weight-loss-mediated joint pain improvement. In March 2026, the TRANSCEND-T2D-1 trial reported A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks in type 2 diabetes patients. The TRIUMPH Phase 3 program includes eight clinical trials evaluating retatrutide in general obesity, type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis. On May 21, 2026, Eli Lilly announced positive topline data from TRIUMPH-1, the pivotal 80-week general obesity trial: participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks, with all three doses (4 mg, 9 mg, and 12 mg) meeting primary and key secondary endpoints. Among participants with a starting BMI of 35 or higher who continued on the drug, weight loss reached up to 30.3% at 104 weeks. These results form the primary basis for the planned NDA submission. A notable safety signal is dysesthesia (abnormal skin sensation), reported in 8.8% (9 mg) and 20.9% (12 mg) of patients vs 0.7% on placebo, and higher discontinuation rates (18.2%) compared to competitors. Eli Lilly plans to file the NDA in Q4 2026, with a potential FDA decision by mid-to-late 2027. The pivotal TRIUMPH-1 trial — the largest in the program at 80 weeks in adults with obesity/overweight without T2D — is the registration study for the weight-management NDA. The TRIUMPH-1 results confirm retatrutide as the highest-efficacy weight-loss compound in clinical development, with additional Phase 3 readouts for type 2 diabetes, cardiovascular disease, and other indications expected through Q3–Q4 2026. Seven additional Phase III readouts are expected throughout 2026, and the overall TRIUMPH program encompasses eight pivotal trials enrolling more than 5,800 participants plus a separate roughly 10,000-patient cardiovascular outcomes trial (TRANSCEND-CV). TRIUMPH-1 secondary biomarker endpoints showed statistically significant improvements across waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein at 80 weeks across all dose groups, though the trial was not powered for cardiovascular event outcomes. At the ADA 2026 Scientific Sessions (June 5–8, New Orleans), Eli Lilly is presenting full TRIUMPH-1 data with complete secondary biomarker endpoints, and TRANSCEND-T2D-1 full data for type 2 diabetes. These presentations represent the first comprehensive peer-reviewed disclosure of the pivotal registration data underpinning the planned Q4 2026 NDA submission. At the ADA 2026 Scientific Sessions (June 7, New Orleans), Eli Lilly presented full data from TRIUMPH-4, the first Phase 3 trial evaluating a pharmacotherapy in adults with both obesity/overweight and knee osteoarthritis. TRIUMPH-4 met all primary and key secondary endpoints at 68 weeks. Participants receiving retatrutide 12 mg achieved 28.7% mean body weight loss (vs 3.3% placebo) — the highest weight loss figure across all retatrutide Phase 3 trials to date — alongside a 75.8% reduction in WOMAC knee pain scores (4.5-point reduction vs 0.5-point placebo). At 68 weeks, 12.0% of the 12 mg group were completely free of knee pain compared with 4.2% in the placebo group. Participants also experienced a 14 mmHg reduction in systolic blood pressure and significant improvements in physical function. The average weight loss of 71.2 lbs in the TRIUMPH-4 12 mg arm represents the highest absolute weight reduction reported in any retatrutide trial to date. These data support a potential sNDA or supplemental indication for musculoskeletal comorbidities alongside the obesity NDA filing planned for Q4 2026. Also known as: LY3437943, Triple G ## Regulatory Status Investigational — Phase 3 (positive pivotal data) TRIUMPH-1 pivotal 80-week obesity trial reported positive topline data May 21, 2026: 28.3% weight loss at 12 mg dose, all doses met endpoints. Up to 30.3% at 104 weeks in BMI ≥35 subgroup. TRIUMPH-4 (obesity + OA, 28.7% at 68 weeks) and TRANSCEND-T2D-1 (T2D, A1C -2.0%) both positive. NDA filing planned Q4 2026. FDA decision expected mid-to-late 2027. Effective: May 2026 [View FDA Source](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss) ## Evidence Snapshot High Evidence Low Medium High Study Type Model Outcome Link Phase 2 Triple agonist (GIP/GLP-1/glucagon) in adults with obesity Up to 24% weight loss over 48 weeks [Source](https://pubmed.ncbi.nlm.nih.gov/37351564/) Phase 3 (TRIUMPH-4) Adults with obesity and knee osteoarthritis (12 mg dose, 68 weeks) 28.7% mean weight loss; 75.8% reduction in WOMAC knee pain; >12.5% completely pain-free [Source](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) Phase 3 (TRANSCEND-T2D-1) Adults with type 2 diabetes, 40 weeks A1C reductions of up to 2.0%; weight loss of up to 36.6 lbs (16.8%) [Source](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html) Phase 3 (TRIUMPH) Retatrutide in obesity with osteoarthritis Average 71.2 lbs weight loss with substantial osteoarthritis pain relief — first successful Phase 3 for weight-loss-mediated joint improvement [Source](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) Phase 3 (TRIUMPH-1) Adults with obesity/overweight without T2D, 80 weeks (pivotal registrational trial) 28.3% mean weight loss at 12 mg dose; up to 30.3% at 104 weeks in BMI ≥35 subgroup; all doses met primary and key secondary endpoints [Source](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss) Phase 3 (TRIUMPH-1 + TRANSCEND-T2D-1 — ADA 2026 full data) Full data presentations at ADA 2026 Scientific Sessions (June 5–8, 2026): TRIUMPH-1 complete secondary endpoints and TRANSCEND-T2D-1 T2D data TRIUMPH-1: 28.3% weight loss (12 mg, 80 wks); significant improvements in waist circumference, non-HDL cholesterol, triglycerides, SBP, and hsCRP. TRANSCEND-T2D-1: A1C −2.0%, weight −16.8% at 40 wks. Dysesthesia in 20.9% at 12 mg (vs 0.7% placebo) confirmed as key differentiated safety signal. [Source](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss) Phase 3 (TRIUMPH-4 — ADA 2026, June 7) Adults with obesity/overweight and knee osteoarthritis — 68-week, randomized, double-blind, placebo-controlled 12 mg: 28.7% weight loss (71.2 lbs avg) vs 3.3% placebo; WOMAC knee pain −75.8% (4.5 pts vs 0.5 pts placebo); 12% completely pain-free vs 4.2% placebo; systolic BP −14 mmHg; all primary and key secondary endpoints met [Source](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) ## Commonly Discussed Benefits [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) Researching Retatrutide ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=retatrutide) ## Safety & Cautions - Still in clinical trials; NDA filing planned Q4 2026, FDA decision expected mid-to-late 2027 - Dysesthesia (abnormal skin sensation) reported in 8.8% (9 mg) and 20.9% (12 mg) vs 0.7% placebo - Higher discontinuation rates (18.2%) compared to other GLP-1 class therapies - Gastrointestinal side effects common in trials - Long-term safety data beyond 104 weeks not yet available - Only available through clinical trial enrollment until potential approval ## Comparisons See how Retatrutide compares to related peptides: [Retatrutide vs Amycretin](/compare/retatrutide-vs-amycretin) [Retatrutide vs CagriSema](/compare/retatrutide-vs-cagrisema) [Retatrutide vs CT-388](/compare/retatrutide-vs-ct-388) [Retatrutide vs Efocipegtrutide](/compare/retatrutide-vs-efocipegtrutide) [Retatrutide vs Efpeglenatide](/compare/retatrutide-vs-efpeglenatide) [Retatrutide vs GLP-1-GIP-Lani (Quintuple Agonist)](/compare/retatrutide-vs-glp1-gip-lani) [Retatrutide vs Maridebart Cafraglutide (MariTide)](/compare/retatrutide-vs-maridebart-cafraglutide) [Retatrutide vs MariTide](/compare/retatrutide-vs-maritide) [Retatrutide vs Mazdutide](/compare/retatrutide-vs-mazdutide) [Retatrutide vs NA-931 (Bioglutide)](/compare/retatrutide-vs-na-931) [Retatrutide vs Pep19](/compare/retatrutide-vs-pep19) [Retatrutide vs Semaglutide](/compare/retatrutide-vs-semaglutide) [Retatrutide vs Survodutide](/compare/retatrutide-vs-survodutide) [Retatrutide vs Tirzepatide](/compare/retatrutide-vs-tirzepatide) [Retatrutide vs UBT251](/compare/retatrutide-vs-ubt251) [Retatrutide vs WVE-007](/compare/retatrutide-vs-wve-007) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Jastreboff AM. et al. — Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023 [PubMed](https://pubmed.ncbi.nlm.nih.gov/37351564/) 2. \[2\] Eli Lilly — TRIUMPH-4 Phase 3 results, December 2025 [PubMed](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) 3. \[3\] Eli Lilly — TRANSCEND-T2D-1 Phase 3 topline results, March 2026 [PubMed](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html) 4. \[4\] Giblin MJ. et al. — TRIUMPH registrational clinical trials design: obesity, OSA, and knee OA. Diabetes Obes Metab. 2026 [PubMed](https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70209) 5. \[5\] Eli Lilly — TRIUMPH-1 Phase 3 topline results (28.3% weight loss at 80 weeks), May 21, 2026 [PubMed](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss) 6. \[6\] Eli Lilly — Retatrutide TRIUMPH-1 and TRANSCEND-T2D-1 full data at ADA 2026 Scientific Sessions. June 2026 [PubMed](https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial) 7. \[7\] Lilly — TRIUMPH-4: Retatrutide Delivers Weight Loss and Osteoarthritis Pain Relief, ADA 2026 [PubMed](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) 8. \[8\] TRIUMPH-4: Retatrutide Achieves 28.7% Weight Loss and Marked Knee Pain Reduction — Patient Care Online [PubMed](https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial) ### Keep researching in the app - Log Retatrutide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=retatrutide) [Browse more peptides](/peptides) ## Related Peptides ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/amycretin) [\+ Compare](/compare?select=amycretin)[](https://app.peptrackerpro.com/?add=amycretin) ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/cagrisema) [\+ Compare](/compare?select=cagrisema)[](https://app.peptrackerpro.com/?add=cagrisema) ### CT-388 Medium Evidence An investigational once-weekly subcutaneous dual GLP-1 and GIP receptor agonist from Roche/Genentech (acquired with Carmot Therapeutics for ~$2.7 billion; Roche code RO7795068). CT-388 is engineered as a 'signal-biased' agonist: it potently activates both incretin receptors but recruits little or no beta-arrestin, which is expected to reduce receptor internalization and desensitization and thereby prolong pharmacological activity. In a Phase 1b study it produced ~18.8% placebo-adjusted weight loss at 24 weeks, and in the Phase 2 CT388-103 dose-finding trial (469 adults with obesity/overweight) it delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand; 18.3% treatment-regimen estimand) at the top 24 mg dose, without reaching a plateau. Roche advanced CT-388 into Phase 3 in the first half of 2026, positioning it as a late-entrant competitor to tirzepatide (Zepbound) with a potentially differentiated biased-signaling mechanism. [Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control) [View Details](/peptides/ct-388) [\+ Compare](/compare?select=ct-388)[](https://app.peptrackerpro.com/?add=ct-388) ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. [Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control)[Metabolism](/benefits/metabolism) [View Details](/peptides/efocipegtrutide) [\+ Compare](/compare?select=efocipegtrutide)[](https://app.peptrackerpro.com/?add=efocipegtrutide) ### Efpeglenatide Low Evidence A once-weekly, long-acting GLP-1 receptor agonist from Hanmi Pharmaceutical built on a different molecular backbone than semaglutide or liraglutide: instead of a modified human GLP-1, efpeglenatide uses exendin-4 - the naturally DPP-4-resistant GLP-1 mimic first found in Gila monster venom - fused to a fragment of a human antibody (an IgG4 Fc) through a small polyethylene-glycol (mini-PEG) linker using Hanmi's LAPSCOVERY half-life-extension platform. That design lets one subcutaneous injection lower blood sugar, curb appetite and reduce body weight for a full week. Efpeglenatide is best known for the landmark AMPLITUDE-O cardiovascular outcomes trial (NEJM 2021), in which 4,076 people with type 2 diabetes and cardiovascular or kidney disease had a 27% lower rate of major adverse cardiovascular events (MACE hazard ratio 0.73) and a 32% lower rate of a composite kidney outcome (hazard ratio 0.68) versus placebo - the first cardiovascular outcomes win for an exendin-based GLP-1 and one of the clearest kidney signals in the class, with benefit seen regardless of whether patients were also taking an SGLT2 inhibitor. Originally licensed to Sanofi and then returned to Hanmi in 2020, efpeglenatide is now being advanced primarily for obesity and overweight, with a Phase 3 program that has completed enrollment and a targeted first launch in South Korea in the second half of 2026. It is an investigational (not yet approved) prescription medicine, not a supplement or research chemical. [weight-loss](/benefits/weight-loss)[blood-sugar](/benefits/blood-sugar)[Cardiovascular](/benefits/cardiovascular)[kidney](/benefits/kidney) [View Details](/peptides/efpeglenatide) [\+ Compare](/compare?select=efpeglenatide)[](https://app.peptrackerpro.com/?add=efpeglenatide) ### GLP-1-GIP-Lani (Quintuple Agonist) Low Evidence A first-in-class peptide-drug conjugate that simultaneously activates five metabolic receptors (GLP-1R, GIPR, PPARα, PPARγ, PPARδ), published in Nature in April 2026 with preclinical results surpassing tirzepatide and triple agonists. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/glp1-gip-lani) [\+ Compare](/compare?select=glp1-gip-lani)[](https://app.peptrackerpro.com/?add=glp1-gip-lani) ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/maridebart-cafraglutide) [\+ Compare](/compare?select=maridebart-cafraglutide)[](https://app.peptrackerpro.com/?add=maridebart-cafraglutide) ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/maritide) [\+ Compare](/compare?select=maritide)[](https://app.peptrackerpro.com/?add=maritide) ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/mazdutide) [\+ Compare](/compare?select=mazdutide)[](https://app.peptrackerpro.com/?add=mazdutide) ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/na-931) [\+ Compare](/compare?select=na-931)[](https://app.peptrackerpro.com/?add=na-931) ### Pep19 Low Evidence An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss. [Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Sleep](/benefits/sleep)[cardiometabolic](/benefits/cardiometabolic) [View Details](/peptides/pep19) [\+ Compare](/compare?select=pep19)[](https://app.peptrackerpro.com/?add=pep19) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/survodutide) [\+ Compare](/compare?select=survodutide)[](https://app.peptrackerpro.com/?add=survodutide) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/ubt251) [\+ Compare](/compare?select=ubt251)[](https://app.peptrackerpro.com/?add=ubt251) ### WVE-007 Low Evidence WVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/wve-007) [\+ Compare](/compare?select=wve-007)[](https://app.peptrackerpro.com/?add=wve-007) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.